{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:46:15Z","timestamp":1793094375506,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00345-018-2516-z","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T01:10:16Z","timestamp":1538961016000},"page":"1329-1337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and\/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-3248","authenticated-orcid":false,"given":"Sebastiano","family":"Nazzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Preisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco A.","family":"Mistretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Souli\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luzzago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Carmignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"2516_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"key":"2516_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.01.015","author":"BM Browne","year":"2018","unstructured":"Browne BM, Stensland KD, Moynihan MJ, Canes D (2018) An analysis of staging and treatment trends for upper tract urothelial carcinoma in the national cancer database. Clin Genitourin Cancer. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2018.01.015","journal-title":"Clin Genitourin Cancer"},{"key":"2516_CR3","unstructured":"Professionals S-O. Upper Urinary Tract Urothelial Cell Carcinoma. Uroweb n.d. \n                    http:\/\/uroweb.org\/guideline\/upper-urinary-tract-urothelial-cell-carcinoma\/\n                    \n                   (accessed May 11, 2018)"},{"key":"2516_CR4","first-page":"92","volume":"2017","author":"PE Clark","year":"2017","unstructured":"Clark PE, Hoimes C, Patterson A (2017) NCCN guidelines index table of contents discussion. Bladder Cancer 2017:92","journal-title":"Bladder Cancer"},{"key":"2516_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","volume":"34","author":"MI Milowsky","year":"2016","unstructured":"Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ et al (2016) Guideline on muscle-invasive and metastatic bladder cancer (European association of urology guideline): American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol 34:1945\u20131952. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.65.9797","journal-title":"J Clin Oncol"},{"key":"2516_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT et al (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66:42\u201354. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2013.08.033","journal-title":"Eur Urol"},{"key":"2516_CR7","doi-asserted-by":"publisher","first-page":"e000126","DOI":"10.1136\/esmoopen-2016-000126","volume":"1","author":"JJ Leow","year":"2016","unstructured":"Leow JJ, Chong KT, Chang SL, Bellmunt J (2016) Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open 1:e000126. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2016-000126","journal-title":"ESMO Open"},{"key":"2516_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1200\/JCO.2018.36.6_suppl.407","volume":"36","author":"AJ Birtle","year":"2018","unstructured":"Birtle AJ, Chester JD, Jones RJ, Johnson M, Hill M, Bryan RT et al (2018) Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 36:407\u2013407. \n                    https:\/\/doi.org\/10.1200\/JCO.2018.36.6_suppl.407","journal-title":"J Clin Oncol"},{"key":"2516_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","volume":"35","author":"T Seisen","year":"2017","unstructured":"Seisen T, Krasnow RE, Bellmunt J, Roupr\u00eat M, Leow JJ, Lipsitz SR et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol 35:852\u2013860. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.69.4141","journal-title":"J Clin Oncol"},{"key":"2516_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.urology.2006.01.053","volume":"68","author":"C Kwak","year":"2006","unstructured":"Kwak C, Lee SE, Jeong IG, Ku JH (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68:53\u201357. \n                    https:\/\/doi.org\/10.1016\/j.urology.2006.01.053","journal-title":"Urology"},{"key":"2516_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1442-2042.2004.00841.x","volume":"11","author":"S Suzuki","year":"2004","unstructured":"Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T (2004) Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. Int J Urol 11:456\u2013460. \n                    https:\/\/doi.org\/10.1111\/j.1442-2042.2004.00841.x","journal-title":"Int J Urol"},{"key":"2516_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1442-2042.2008.02114.x","volume":"15","author":"N Soga","year":"2008","unstructured":"Soga N, Arima K, Sugimura Y (2008) Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol Off J Jpn Urol Assoc 15:800\u2013803. \n                    https:\/\/doi.org\/10.1111\/j.1442-2042.2008.02114.x","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"2516_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529\u2013541. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2014.03.003","journal-title":"Eur Urol"},{"key":"2516_CR14","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1002\/cncr.26172","volume":"117","author":"M Vassilakopoulou","year":"2011","unstructured":"Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos M-A et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117:5500\u20135508. \n                    https:\/\/doi.org\/10.1002\/cncr.26172","journal-title":"Cancer"},{"issue":"31","key":"2516_CR15","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.urolonc.2012.11.014","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J et al (2014) Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol 32(31):e17\u2013e24. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2012.11.014","journal-title":"Urol Oncol"},{"key":"2516_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bju.14020","volume":"121","author":"A Necchi","year":"2018","unstructured":"Necchi A, Vullo SL, Mariani L, Moschini M, Hendricksen K, Rink M et al (2018) Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 121:252\u2013259. \n                    https:\/\/doi.org\/10.1111\/bju.14020","journal-title":"BJU Int"},{"key":"2516_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.03.027","author":"S Nazzani","year":"2018","unstructured":"Nazzani S, Bandini M, Marchioni M, Preisser F, Tian Z, Souli\u00e8res D et al (2018) A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. Radiother Oncol J Eur Soc Ther Radiol Oncol. \n                    https:\/\/doi.org\/10.1016\/j.radonc.2018.03.027","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2516_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.11.012","author":"M Marchioni","year":"2017","unstructured":"Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L et al (2017) Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. Eur Urol Focus. \n                    https:\/\/doi.org\/10.1016\/j.euf.2017.11.012","journal-title":"Eur Urol Focus"},{"key":"2516_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.05.001","author":"S Nazzani","year":"2018","unstructured":"Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF et al (2018) In-hospital length of stay after major oncological surgical procedures. Eur J Surg Oncol. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2018.05.001","journal-title":"Eur J Surg Oncol"},{"key":"2516_CR20","doi-asserted-by":"publisher","first-page":"e1166","DOI":"10.1016\/j.juro.2018.03.098","volume":"199","author":"J Hoffman-Censits","year":"2018","unstructured":"Hoffman-Censits J, Puligandla M, Trabulsi E, Plimack E, Kessler E, Matin SF et al (2018) LBA26 PHASE II TRIAL OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY EXTIRPATIVE SURGERY FOR PATIENTS WITH HIGH GRADE UPPER TRACT UROTHELIAL CARCINOMA (HG UTUC): RESULTS FROM ECOG-ACRIN 8141. J Urol 199:e1166\u2013e1167. \n                    https:\/\/doi.org\/10.1016\/j.juro.2018.03.098","journal-title":"J Urol"},{"key":"2516_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2017.12.054","volume":"200","author":"RS Liao","year":"2018","unstructured":"Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH et al (2018) Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol 200:68\u201373. \n                    https:\/\/doi.org\/10.1016\/j.juro.2017.12.054","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2516-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2516-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2516-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T19:05:47Z","timestamp":1570475147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2516-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2516"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2516-z","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sebastiano Nazzani certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment\/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosures"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We affirm that all authors have complied with the principles of the World Journal of Urology regarding ethical responsibilities of authors and compliance with ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}